Physicians Financial Services Inc. Has $5.65 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Physicians Financial Services Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 17,547 shares of the medical research company’s stock after selling 565 shares during the quarter. Amgen accounts for approximately 1.8% of Physicians Financial Services Inc.’s portfolio, making the stock its 13th biggest position. Physicians Financial Services Inc.’s holdings in Amgen were worth $5,654,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Capital International Investors lifted its stake in shares of Amgen by 547.8% in the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock valued at $1,991,738,000 after buying an additional 5,923,915 shares in the last quarter. Pathway Financial Advisers LLC boosted its stake in Amgen by 33,125.4% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after purchasing an additional 4,446,757 shares during the last quarter. Vanguard Group Inc. increased its holdings in Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock worth $14,809,720,000 after purchasing an additional 3,045,657 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company’s stock worth $8,130,610,000 after purchasing an additional 2,486,882 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of Amgen by 137.1% in the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock valued at $676,984,000 after purchasing an additional 1,377,007 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN traded up $2.13 during trading hours on Friday, hitting $324.04. The company had a trading volume of 119,055 shares, compared to its average volume of 2,401,752. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market capitalization of $174.18 billion, a price-to-earnings ratio of 41.22, a PEG ratio of 2.79 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The firm has a 50 day simple moving average of $323.96 and a 200 day simple moving average of $316.68.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the company earned $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities research analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.78%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. Barclays increased their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Morgan Stanley dropped their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 11th. Finally, UBS Group reduced their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $333.50.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.